ArticleFrontiers in immunology2021
Persistent High Percentage of HLA-DR
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed.
- Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study.Signal transduction and targeted therapy · 2026Trial
- Valganciclovir modulates the tumor necrosis factor axis molecules expression and CD4+ T-cell subsets in disseminated Kaposi Sarcoma patients.Clinical and experimental immunology · 2024Trial
- Distinct CD8iScience · 2026Article
- Distinct cellular signatures in aplastic and intermittent phenotypes of immune effector cell-associated hematotoxicity.Annals of hematology · 2026Article
- HBsAg loss in chronic hepatitis B patients with an HBsAg decline plateau can be enhanced by intermittent PEG-IFN treatment.Frontiers in cellular and infection microbiology · 2026Observational
- Body composition measurement and diabetes - A new perspective on development of antibodies after SARS-CoV-2 booster vaccination.Journal of diabetes and metabolic disorders · 2025Article
- Article
- The crucial role of immune factors in susceptibility to SARS-CoV-2 infection and severity of COVID-19.Molecular genetics and genomics : MGG · 2025Article
- Cytotoxic T-cell activation profile in critically ill children with malignancies and hemophagocytic lymphohistiocytosis.Pediatric research · 2025Article
- Intraperitoneal infusion of NKG2D CAR-NK cells induces endogenous CD8Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Activated Interferon-γ-Positive T Lymphocytes and Cytokine Signatures in Patients With Postinfectious Cough.MedComm · 2025Article
- SARS-CoV-2 Infection in Children: Revisiting Host-Virus Interactions Through Post-Infection Immune Profiling.Pathogens (Basel, Switzerland) · 2025Article
- Machine Learning Reveals the Value of Unconventional T Lymphocytes in Sepsis and Prognosis of Elderly Patients With Severe Lower Respiratory Tract Infections.Journal of clinical laboratory analysis · 2025Article
- Longitudinal Immunoprofiling of the CD8Vaccines · 2025Article
- Role of antiviral CD8+ T cell immunity to SARS-CoV-2 infection and vaccination.Journal of virology · 2025Review
- CD31 + naïve T cells associate with immunosenescence and responsiveness to multiple vaccines in older adults.Immunity & ageing : I & A · 2025Article
- Tracking immune dysregulation in COVID-19: lymphocyte dynamics from hospitalization to recovery.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025Article
- The CD38Frontiers in immunology · 2025Article
- Distinct Omicron longitudinal memory T cell profile and T cell receptor repertoire associated with COVID-19 hospitalisation.Frontiers in immunology · 2025Article
- Decoding NAD+ Metabolism in COVID-19: Implications for Immune Modulation and Therapy.Vaccines · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The global outbreak of coronavirus disease 2019 (COVID-19) has turned into a worldwide public health crisis and caused more than 100,000,000 severe cases. Progressive lymphopenia, especially in T cells, was a prominent clinical feature of severe COVID-19. Activated HLA-DR Methods: A total of 42 COVID-19 patients, including 32 mild or moderate and 10 severe or critical cases, who received care at Beijing Ditan Hospital were recruited into this retrospective study. Blood samples were first collected within 3 days of the hospital admission and once every 3-7 days during hospitalization. The longitudinal flow cytometric data were examined during hospitalization. Moreover, we evaluated serum levels of 45 cytokines/chemokines/growth factors and 14 soluble checkpoints using Luminex multiplex assay longitudinally. Results: We revealed that the HLA-DR Conclusions: Our findings indicated that HLA-DR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.